arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

RECURSION PHARMACEUTICALS, INC.

RXRX
$3.49 ▼ -0.38 (-9.82%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
29 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

RECURSION PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.9B
Dividend Yield —
Revenue Growth 258.5% ↗
Op. Margin None
ROIC -13.6% ↗
FCF / Share $-0.14 ↗
Trailing P/E —
Price / Book 2.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

29-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$18.55M
↑ +258.5% —
Net Income Profit after all expenses
$-119.04M
↑ +26.6% —
Operating Margin Operating profit as % of sales
-304.8%
↑ +19.2% —
FCF / Share Free cash flow per share
$-0.14
↑ +28.0% —
Long-Term Debt Long-term obligations
$744.00K
↓ -94.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
15
Cash Quality ↓
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 8 years · 29 quarters